CYTOKINETICS INC
About CYTOKINETICS INC
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $88.0M
- Net income
- -$785.0M
- Total assets
- $1.4B
- Market cap
- $9.7B
- Operating margin
- -695.4%
- Net margin
- -891.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $88.0M
- Operating expenses
- $700.3M
- Operating income
- -$612.3M
- Income tax
- $0
- Net income
- -$785.0M
- EPS (basic)
- $-6.54
- EPS (diluted)
- $-6.54
Balance sheet
- Total assets
- $1.4B
- Current assets
- $917.0M
- Total liabilities
- $2.1B
- Current liabilities
- $202.5M
- Shareholders’ equity
- -$659.6M
Cash flow
- Operating cash flow
- -$510.0M
- Investing cash flow
- $16.7M
- Financing cash flow
- $524.5M
- Net cash flow
- $30.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $9.7B
- EPS (diluted)
- $-6.54
- Shares outstanding
- 142.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $785.0M in FY2025.
- Revenue grew 58% from FY2020 to FY2025.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CYTOKINETICS INC.
Write a review
News about CYTOKINETICS INC
News & sentiment via Polygon.io
